Skip to main content
OpenTrials
Completed

NCT Number: NCT06823180

Hydromorphone Hydrochloride Epidural Preemptive Analgesia for Postoperative Pain After Cesarean Section

Acute pain often occurs after cesarean section, which can lead to stress and inflammatory response in the body, which will not only affect the postpartum recovery speed of the puerpera, but also inhibit the secretion of prolactin to a certain extent and reduce the secretion of milk. Epidural anesthesia is a common anesthesia method for cesarean section, which has the advantages of easy operation and little influence on the fetus. Preemptive analgesia can effectively block the transmission of harmful stimuli and reduce the degree of pain after cesarean section. Hydromorphone hydrochloride is a derivative of morphine, which has the advantages of rapid onset and good analgesic effect, and has been widely used in clinic. However, it is not clear whether epidural injection of hydromorphone hydrochloride for preanalgesia can bring clinical benefits to puerpera, and the optimal dose of hydromorphone hydrochloride for cesarean section is also unclear.

The parturient women who met the inclusion criteria were randomly divided into 3 groups: control group, hydromorphone hydrochloride low-dose administration group and hydromorphone hydrochloride high-dose administration group. All women received epidural combined subarachnoid anesthesia. 15min before the end of the operation, the low-dose hydromorphone hydrochloride group was injected with 0.1mg hydromorphone hydrochloride in the epidural space, the high-dose hydromorphone hydrochloride group was injected with 0.3mg hydromorphone hydrochloride in the epidural space, and the control group was injected with 0.9% sodium chloride injection. Post-obstetric visual analogue scale (VAS) was followed up to record PCA compression times, gastrointestinal peristalsis recovery time, getting out of bed time, lactation time, and related adverse reactions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, 330038, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Parturients with indications for cesarean section;
  • American Association of Anesthesiologists (ASA) Grade I - II;
  • No history of sedative drugs or opioid abuse;
  • Volunteer to join the study

Exclusion criteria

  • People with coagulation disorders;
  • preoperative use of analgesia, non-steroidal drugs;
  • Abnormal liver and kidney function;
  • Postoperative drainage is urgently needed.

Treatment and study plan

Hydromorphone hydrochloride low dose

Drug

15min before the end of the operation, 0.1mg hydromorphone hydrochloride was injected into the epidural space in the low-dose group for preemptive analgesia.

Hydromorphone hydrochloride high dose

Drug

15min before the end of the operation, 0.3mg hydromorphone hydrochloride was injected into the epidural space in the high-dose group for preemptive analgesia.

0.9% Sodium Chloride

Drug

15min before the end of the operation, 0.9% sodium chloride injection was given in the control group.

Primary outcomes

  1. VAS score

    Time frame: 24 hours after surgery

    VAS score was used to evaluate the pain in each period after obstetric surgery. A strip marked with a scale of 0-10 was taken, where 0 indicated no pain, the pain degree increased with the increase of the score, and 10 indicated the most pain. The mothers chose the score matching their own pain degree. Mild pain: 0<VAS<4 ; Moderate pain :4 ≤VAS< 7; Severe pain :7 ≤VAS<9; Extreme pain: VAS≥9.

Secondary outcomes

  1. The number of PCA compressions after surgery

    Time frame: 48 hours after surgery

  2. Satisfaction evaluation

    Time frame: Before discharge

    Patients' satisfaction was assessed by HCAHPS survey. The survey was designed to assess patient inpatient experience, including nurse care, physician communication, hospital environment, hospital experience, discharge information provision, and overall hospital evaluation.

  3. Gastrointestinal peristalsis recovery time

    Time frame: 72 hours after surgery

    The recovery time of bowel sound, anal exhaust and defecation were recorded.

  4. The time it takes to get out of bed for the first time after surgery

    Time frame: 96 hours after surgery

  5. The time between the end of surgery and lactation

    Time frame: 72 hours after surgery

  6. Postoperative nausea and vomiting(PONV)

    Time frame: 72 hours after surgery

    PONV rating standards of WHO are adopted. Specifically: Grade I is no nausea, vomiting; Grade II was mild nausea, abdominal discomfort, but no vomiting; Grade III is nausea and vomiting, but there is no content spit out; Grade IV is severe vomiting, with vomiting of stomach contents and requiring medical control.

  7. pruritus

    Time frame: 72 hours after surgery

    The numeric rating scale (NRS) was used to evaluate the degree of postoperative pruritus. Itching is numerically graded on the NRS scale, with 0 indicating no itching and 10 indicating the most severe itching. The degree of itching increased with the increase of the score. Mild pruritus :0<NRS<4 ; Moderate pruritus :4 ≤NRS< 7; Severe pruritus :7 ≤NRS<9; Extreme pruritus :NRS≥9.

Sponsors and collaborators

Lead sponsor

Liquan Liang

Other

Registry information

Official study title

Clinical Effect of Hydromorphone Hydrochloride Epidural Preemptive Analgesia on Postoperative Pain After Cesarean Section

Acronym: HHEPA

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Feb 12, 2025
Registry last updated
Sep 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.